The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference
Open accessAbstract
To cite this article: Schram ME, Spuls PI, Leeflang MMG, Lindeboom R, Bos JD, Schmitt J. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy 2012; 67: 99–106. Background: Demonstration of adequate reliability and validity is sufficient for concluding that an instrument is applicable for descriptive and predictive purposes, but before we can confidently use an outcome measure in clinical trials, the responsiveness (synonymous with sensitivity to change) and minimal clinically important difference (MCID) should be known. With this study, we aimed to assess responsiveness and MCID of four outcome measures used in atopic eczema: the Severity Scoring of Atopic Dermatitis (SCORAD), the objective SCORAD, Eczema Area and Severity Index (EASI), and the Patient‐Oriented Eczema Measure (POEM). Methods: Data of three randomized controlled trials were used. To demonstrate responsiveness, we plotted receiver operating characteristic (ROC) curves. MCID was estimated using mean change scores of patients that showed a relevant improvement. Bland and Altman methods were used to quantify the limits of agreement. Results: Area under the ROC curve for the SCORAD was 0.70 [95% confidence interval (CI): 0.61–0.78], for the objective SCORAD, 0.73 (95% CI: 0.70–0.77), for the EASI, 0.67 (95% CI: 0.60–0.76), and for the POEM, 0.67 (95% CI: 0.59–0.75). Scores above 0.70 represent a fair responsiveness. The MCID was 8.7 points for the SCORAD, 8.2 for the objective SCORAD, 6.6 for the EASI, and 3.4 for the POEM. Conclusion: The objective SCORAD and SCORAD showed a fair responsiveness. The MCIDs are an important prerequisite for the interpretation of published eczema trials and for the planning/sample size estimation of future trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1990) · Choice Reviews Online · doi:10.5860/choice.27-3338 · Cited by 35,305
Hosmer, D. W., & Lemeshow, S. (2000) · doi:10.1002/0471722146 · Cited by 20,302
Jaeschke, R., Singer, J., & Guyatt, G. H. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90005-6 · Cited by 4,982
Mokkink, L. B., Terwee, C. B., Patrick, D. L., Alonso, J., Stratford, P. W., Knol, D. L., Bouter, L. M., & de Vet, H. C. W. (2010) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.02.006 · Cited by 4,465
Beasley, R. (1998) · The Lancet · doi:10.1016/s0140-6736(97)07302-9 · Cited by 3,389
Revicki, D., Hays, R. D., Cella, D., & Sloan, J. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.03.012 · Cited by 2,362
Severity Scoring of Atopic Dermatitis: The SCORAD Index
(2009) · Dermatology · doi:10.1159/000247298 · Cited by 2,273
Mokkink, L. B., Terwee, C. B., Knol, D. L., Stratford, P. W., Alonso, J., Patrick, D. L., Bouter, L. M., & de Vet, H. C. (2010) · BMC Medical Research Methodology · doi:10.1186/1471-2288-10-22 · Cited by 1,834
Defining clinically meaningful change in health-related quality of life
Crosby, R. D., Kolotkin, R. L., & Williams, G. R. (2003) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(03)00044-1 · Cited by 1,332
Cited by
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
Beck, L. A., Thaçi, D., Hamilton, J. D., Graham, N. M., Bieber, T., Rocklin, R., Ming, J. E., Ren, H., Kao, R., Simpson, E., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314768 · Cited by 1,421
Guidelines of care for the management of atopic dermatitis
Eichenfield, L. F., Tom, W. L., Chamlin, S. L., Feldman, S. R., Hanifin, J. M., Simpson, E. L., Berger, T. G., Bergman, J. N., Cohen, D. E., Cooper, K. D., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.10.010 · Cited by 1,277
Schoemaker, A. A., Sprikkelman, A. B., Grimshaw, K. E., Roberts, G., Grabenhenrich, L., Rosenfeld, L., Siegert, S., Dubakiene, R., Rudzeviciene, O., Reche, M., et al. (2015) · Allergy · doi:10.1111/all.12630 · Cited by 484
Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb
Wollenberg, A., Howell, M. D., Guttman-Yassky, E., Silverberg, J. I., Kell, C., Ranade, K., Moate, R., & van der Merwe, R. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.05.029 · Cited by 409
Metadata
- Authors
- Schram, M. E., Spuls, P. I., Leeflang, M. M. G., Lindeboom, R., Bos, J. D., & Schmitt, J.
- Venue
- Allergy
- Publisher
- Wiley
- Published
- 2011-09-27
- Volume
- 67
- Issue
- 1
- Pages
- 99-106
- ISSN
- 0105-4538 (ISSN-L)
- 1398-9995
- OpenAlex
- W1583257755
- Cited by
- 383
- References
- 23
- FWCI
- 11.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. https://app.cochat.ai/papers/10.1111/j.1398-9995.2011.02719.x
- The paper
- Schram, M. E., Spuls, P. I., Leeflang, M. M. G., Lindeboom, R., Bos, J. D., & Schmitt, J. (2012). EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy. https://doi.org/10.1111/j.1398-9995.2011.02719.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.